Division of Clinical Immunology and Allergy, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA.
Immunol Allergy Clin North Am. 2010 Aug;30(3):425-39. doi: 10.1016/j.iac.2010.05.002. Epub 2010 Jul 8.
Atopic dermatitis can be a challenging disease to treat, often having a chronic or relapsing course. For patients with moderate to severe disease, it can result in significant morbidity and affect quality of life of patients or families. Current treatment can be associated with side effects or patient and caregiver concerns about use. Recent advances in the understanding of barrier defects and innate and adaptive immune systemic abnormalities in atopic dermatitis have provided potential new targets for therapeutic intervention. These advances include antimicrobial peptides, antistaphylococcal toxin strategies, Th2 cytokine inhibitors, and modulation of pruritus at the neuromediator level.
特应性皮炎的治疗具有一定挑战性,通常呈慢性或复发性病程。对于中重度疾病患者,其发病率较高,严重影响患者或其家庭的生活质量。目前的治疗方法可能存在副作用,或患者及其照护者对药物使用的顾虑。特应性皮炎的皮肤屏障缺陷、固有和适应性免疫系统异常的相关机制得到进一步阐释,为治疗干预提供了新的潜在靶点。这些进展包括抗菌肽、抗葡萄球菌毒素策略、Th2 细胞因子抑制剂,以及通过神经递质水平调节瘙痒。